Women are spending hours hunting pharmacies and travelling across counties to keep their estradiol patches, after the FDA removed a more than 20-year-old black box warning and demand spiked. Prescriptions for estrogen patches have climbed sharply, with HealthVerity data showing a 162 percent increase in the last two years, and hospitals and clinicians reporting localized shortages and daily operational strain. The American Society of Health-System Pharmacists listed multiple estradiol transdermal patch products as in shortage in its April 22, 2026 bulletin, while the FDA hasn't declared a shortage and said supply is holding up, "but barely." Supply and manufacturing problems reported to regulators overseas, and temporary approval paths for imports, suggest some national-registered products may remain limited through the end of 2026.

Hospitals and clinics are scrambling because demand for menopausal hormone therapy jumped after the FDA removed its black box warning in November 2025, following a reevaluation of older evidence that had discouraged routine use of hormone replacement therapy. The immediate effect is tangible: clinicians report patients calling daily, pharmacists tracing stock across counties, and staff rerouting care so patients don't miss doses.

Where shortages are showing up

The American Society of Health-System Pharmacists is listing multiple estradiol transdermal patch products as in shortage, and its April 22, 2026 bulletin names specific brands that are on back order or have no estimated restock date. That tracking contrasts with the Food and Drug Administration, which hasn't declared an estradiol shortage under its own methodology and told clinicians supply is holding up, "but barely." The discrepancy reflects different measurement approaches and the localised nature of stockouts, rather than a single nationwide outage.

Clinicians describe the practical toll. Dr. Susan Loeb-Zeitlin, director of the Women’s Midlife Center at Weill Cornell Medicine, said, "You can get them, but it takes a lot of time and effort when we're all so busy at this time of our lives." In Iowa, Dr. Francesca Turner said coordinating between nurses, pharmacists and patients to locate patches has become a near-daily task. Hospitals and outpatient clinics report daily operational strain as staff chase inventory to avoid missed treatments.

Patient surveys confirm the disruption at the individual level. A Midi Health survey of nearly 8,000 women found 44 percent of respondents had difficulty filling an estradiol patch prescription, and 34 percent of those said the shortage was affecting their well-being. Clinicians report patients travelling between counties and relying on online pharmacies to locate products, which adds cost and stress for people managing menopausal symptoms such as hot flashes, sleep disruption and cognitive complaints.

Manufacturing bottlenecks and international responses

Supply trouble isn't only local. National regulatory notices show manufacturers have reported production problems that shifted demand to other brands and created backorders. Australia’s Therapeutic Goods Administration said Sandoz and Juno Pharmaceuticals notified it of shortages for estradiol and combination estradiol-norethisterone transdermal patches.

Mastheads

The TGA also described some products as in short supply because manufacturing problems shifted demand to alternative brands.

To reduce disruption, the TGA approved access to overseas-registered alternatives under section 19A of the Therapeutic Goods Act and implemented a Serious Scarcity Substitution Instrument. That instrument lets pharmacists dispense an alternative brand or strength without a new prescription in jurisdictions where the rule applies, a step intended to preserve continuity of care while supply lines are adjusted. The Australian regulator also projected that supply of some nationally registered HRT patch products could remain limited through the end of 2026.

Clinicians and supply-chain experts describe the situation as a global mismatch between a rapid rise in demand and the time it takes manufacturers to expand production capacity or requalify foreign supply lines. In short, the surge in prescriptions has outpaced production and regulatory processes needed to bring new or imported supplies online.

Prescribers and pharmacy systems have been advising interim approaches. QuickMD and academic clinicians recommend that when a preferred patch is unavailable, prescribers can switch patients to another patch brand or move to a different delivery form, including gels, creams, sprays or oral estrogen, depending on medical history and treatment goals. In jurisdictions that have issued temporary approvals or substitution rules, pharmacists may be able to substitute without a new prescription, which eases access for some patients.

But substitution isn't a simple swap for every patient. Different formulations and routes of administration have different dosing, absorption and risk profiles, and clinicians need to weigh those factors against each patient's cardiovascular and cancer history. That clinical judgement, plus time spent coordinating alternative supplies, is why staff in many clinics report increased workload while the situation persists.

Pharmacies are taking a range of practical steps. Some are able to order alternative brands or import overseas-registered versions; others face backorders with no clear restock timelines. Where regulators have created temporary pathways, pharmacists have a clearer route to dispense alternatives, but that route depends on the specifics of national rules and of available stock.

For patients, clinicians recommend a few short-term steps. Contact nearby pharmacies early to check stock, ask a pharmacist about alternative manufacturers or strengths, and, if appropriate, discuss switching routes of administration with a prescriber.

In places with substitution instruments or emergency import authorizations, a pharmacist may be able to provide an alternative without a fresh prescription. Even with those options, clinicians describe daily coordination to maintain continuity of care.

Related Articles

Australian regulators warned some nationally registered patch products could remain limited through the end of 2026, a concrete timeline that shows how the post-warning surge in demand has outpaced production and regulatory fixes. Originally reported by CNBC.

This article was created with AI assistance.